Uncovering the manufacturer and drug properties of ensidipine

Ensidipine, also known as Idhifa or Enasidenib by the majority of people in the medical field, was born from the well-known American pharmaceutical company Celgene. With its unique mechanism, this drug has shown excellent results in the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) carrying IDH2 gene mutations. As an inhibitor of isocitrate dehydrogenase-2 (IDH2), it mainly regulates the level of the specific metabolite 2-hydroxyglutarate (2-HG) in the body by inhibiting the activity of mutated IDH2 enzyme, thereby promoting the normal differentiation of leukemia cells and achieving the purpose of treating AML.

The research and development process of ensidipine integrated many cutting-edge scientific research and in-depth clinical trials. Its efficacy in practical applications has been widely clinically verified, bringing new life to many AML patients. Research data shows that many patients who received ensidipine treatment achieved complete remission or significant improvement in some hematological indicators, and this remission state can last for a long time.

With the wide application of ensidipine in the medical field, its generic drugs have gradually entered the market. For example, ZISKA Pharmaceuticals in Bangladesh and Lucius Pharmaceuticals in Laos have launched generic versions of this drug. These generic drugs provide patients with more medication options at more economical prices. However, whether you choose original drugs or generic drugs, ensuring that the source of the drug is regular and of reliable quality is the key to ensuring safe and effective treatment.

In addition, the specifications and storage conditions of ensidipine are also important information that patients need to pay attention to when taking the drug. Typically, ensidipine is supplied as 50 mg tablets, with each bottle containing 30 tablets. In order to ensure the effectiveness and safety of the drug, it needs to be stored in a constant temperature environment of 20°C to 25°C, and should be stored in the original sealed container and kept dry to prevent the tablets from getting damp.

To sum up, ensidipine, as an outstanding research and development achievement of Celgene Pharmaceuticals, not only provides a new treatment strategy for AML patients with IDH2 gene mutations, but also meets the medication needs of different patients with its various forms of original drugs and generic drugs, giving them hope of regaining their health.